Invited Speakers

International Speakers

Associate Professor Clemens Decristoforo,

Clinical Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria

Dr. Clemens Decristoforo is radiopharmacist and Associate Professor in Radiopharmacy (Univ.Doz., since 2001) at the Department of Nuclear Medicine of the Medical University Innsbruck. He did his PhD in Radiopharmacy and a post doc at the Nuclear Medicine Research Laboratory at St. Bart`s in London, UK. From 2009-2010 he worked as radiopharmaceutical scientist at the IAEA headquarters in Vienna. His main research area is in the preclinical development of peptide based radiopharmaceuticals for molecular imaging and targeted radionuclide therapy in oncology with a focus on radiometals with more than 100 publications and world-wide research collaborations. Several ^99mTc and ⁶⁸Ga labeled peptides have been translated from radiopharmaceutical research to the clinic. He is in the editorial board of the European Journal of Nuclear Medicine and Molecular imaging and other NM-related journals. He is past chairman of the Radiopharmacy committee and member of the Legislation Working Group of the EANM, member of the expert group on radiopharmaceuticals (Group 14) of the European Pharmacopeia. For many years he is involved in the organization of the European Symposia on Radiopharmacy and Radiopharmaceuticals (ESRR, local organizer 2003) as well as in the scientific committee of the annual EANM meeting. He is participating in many activities regarding radiopharmaceutical legislation on a European level.

Professor Chaitanya Divgi, MD

Professor of Radiology; Vice-Chair, Research Department of Radiology Chair, Joint Radiation Safety Committee Columbia University Director, Nuclear Medicine/PET Columbia University Medical Center, USA

Proudly sponsored by Genzyme

After graduating from St. John’s Medical College in Bangalore, India, in 1976, Dr. Divgi went to the Radiation Medicine Center, Bhabha Atomic Research Centre, Bombay, India, where he obtained a Diploma in Radiation (Nuclear) Medicine in 1978. He subsequently worked at the Jaslok Hospital & Research Centre in Bombay, with Dr. R.D. Lele, before going to Abu Dhabi as Head of Nuclear Medicine in 1982. Dr. Divgi came to Memorial Sloan-Kettering Cancer Center, New York, NY, in 1985, and was there until May 2006, when he joined the University of Pennsylvania. In April 2011, he joined Columbia University as Director, Nuclear Medicine and PET and Vice-Chair, Research, Department of Radiology at Columbia University.

In addition to targeted radiopharmaceutical therapy and diagnostic clinical single photon and PET Nuclear Medicine, Dr. Divgi’s research interests include antigen-binding constructs. He has conducted several immunoPET and radioimmunotherapy studies in a variety of solid tumors including ovary, colon, kidney, and biliary cancers. Dr. Divgi has a close collaboration with the Ludwig Institute for Cancer Research, having started in 1987 at MSKCC as a Clinical Research Fellow with Dr. Lloyd J. Old, Director of the LICR, New York branch.

Professor Peter F. Faulhaber M.D, M.A

Director, Clinical PET, Case Western Reserve University, USA

Proudly sponsored by Insight

Dr. Faulhaber is Director of Clinical PET University Hospitals Case Medical Center and Professor of Radiology Case Western Reserve University. He has worked in the field of Positron Emission Tomography for 34 years, starting out as a research technologist at the University of Chicago prior to medical school. At University Case Medical Center, he was steward of the transition of PET from a research tool to a clinical modality, and finally the transition to PET/CT. His clinical interests include all aspects of PET imaging in oncology, neurology and cardiology. Dr. Faulhaber is particularly interested in response to therapy evaluations and patient outcomes based on PET imaging. He has numerous research collaborations with clinical and basic research colleagues in ovarian, prostate and breast cancer, for example. Dr Faulhaber is involved in the implementation of the new modality PET/MRI at University Hospitals Case Medical Center. He is part of a recent State of Ohio Third Frontier Award in PET/MRI applications in breast cancer. Dr. Faulhaber has a passion for education in PET/CT imaging and lectures nationally and internationally. He began to write podcasts to promote excellence in PET imaging on PET four years ago, available at clinicalpetcast.com.

Brenda J. King, CNMT, FSNMMI-TS

2012-13 SNMMI-TS President

Brenda J. King, CNMT, FSNMMI-TS, is owner of BJ King & Associates, LLC, a company that offers advanced imaging accreditation consultation to hospitals and private practice imaging centers nationwide. She began her career in nuclear medicine technology more than 35 years ago as a radiopharmacy/nuclear medicine technologist at Cedars-Sinai Medical Center in Los Angeles, Calif. She then moved to work on the industry side, working for Amersham, Bristol Meyers Squibb Medical Imaging and Cardinal Health. King has served in many positions in SNMMI-TS, most recently as president, Speaker for the National Council of Representatives, on the SNMMI House of Delegates and on the SNMMI-TS Executive Board, as well as on the SNMMI Nominating Committee, Committee on Councils, Committee on Chapters and the SNMMI-TS Physician-Technologist Task Force. She has also served the SNMMI-TS Pacific Southwest Chapter as president, president-elect and secretary and on multiple committees. In addition, King is a member of the Association of Black Cardiologists, the Association of Nuclear Cardiology, the Los Angeles Radiologic Society and the Association of Molecular Imaging. She has received a number of awards for her work in nuclear medicine technology, including the SNMTS President’s Distinguished Service Award, SNMTS Officer’s Award and Bristol Meyers Squibb Clinical Specialist of the Year. She has published three peer-reviewed articles and has participated in 25 invited speaker presentations.

Dr Jamshid Maddahi Professor Jamshid Maddahi, MD, FACC, FASNC

Professor of Molecular and Medical Pharmacology (Nuclear Medicine) Professor of Medicine (Cardiology) David Geffen School of Medicine, UCLA, USA

Dr. Jamshid Maddahi is internationally recognized as a leader and expert in cardiovascular disease research, teaching and patient care. Dr. Maddahi obtained his MD degree with Distinguished Honors in 1975 from Tehran University. He subsequently completed his residency and fellowship training in the United States in Internal Medicine, Cardiovascular Diseases, Nuclear Medicine, and Nuclear cardiology. Dr. Maddahi began his academic and research career in 1977 in the field of Nuclear Cardiology. His pioneering and collaborative research in this field has led to several seminal articles on clinical applications of Nuclear Cardiology. The scope of his research has included development and validation of methods for assessment of myocardial perfusion, detection and risk stratification of patients with suspected or known coronary artery disease, assessment of myocardial viability and cost effectiveness of nuclear imaging in the management of patients. At the present, Nuclear Cardiology has become a standard technique in cardiology. In the US alone, more than 10 million Nuclear Cardiology procedures are done each year.

In 1990, Dr. Maddahi became Director of Clinical PET Center at UCLA with the overall goal of extending applications of the new technique of PET scanning into the clinical arena in oncology, cardiology and neurology. Over the ensuing years, the pioneering work of the UCLA team led to ever increasing role of the PET scanning technique in management of patients with cancer and heart disease. In 1998, Dr. Maddahi extended his research interest to the field of Cardiac CT. In 2007, Dr. Maddahi lead the clinical investigations on the use of a new F-18 labeled PET perfusion agent. This tracer, that is currently in Pahse II clinical trials, has the potential of becoming the dominant tracer for noninvasive assessment of coronary artery disease.

Dr. Maddahi became Assistant Professor of Medicine at UCLA in 1981 and is currently Clinical Professor (level 6) of Molecular and Medical Pharmacology (Nuclear Medicine) and Medicine (Cardiology) at David Geffen School of Medicine at UCLA. He is also Director of Biomedical Imaging Institute. The initiative of this institute has been to elevate the quality of cardiac imaging centers in the community. During his academic career, Dr. Maddahi has received several million Dollars of research funding from the National Institute of Health and non-governmental sources. He has authored more than 200 original research articles, abstracts and book chapters. For his scientific contributions, Dr. Maddahi has received numerous national and international awards from medical societies. From the Society of Nuclear Medicine he has received the first annual Norman D. Poe Scholarship Award (1981), Distinguishes Scientist Award (1988), Herman Blumgart Award (2004), and has been Distinguished Lecturer in 1995 (Winfield Evan Memorial) and 1997 (Taplin Memorial). In 1999, Professor Maddahi received The Homi Bhabha Award for Outstanding Contributions to Nuclear Cardiology, from The Indian Society of Nuclear Cardiology.

As an educator, Dr. Maddahi has trained many physicians in the subspecialties of Cardiology, Nuclear Medicine, and Radiology. He has also mentored many foreign physicians who have then assumed high academic positions in their native countries. His expertise is widely sought after as director, member of organizing committees, and lecturer for numerous national and international scientific conferences and symposia. So far Dr. Maddahi has delivered more than 1100 lectures worldwide. He has received the 'Faculty Teaching Award' of the UCLA Cardiology Division on two occasions. As a clinician, Dr. Maddahi is a high profile cardiovascular consultant and is highly regarded by his patients for his knowledge and compassion. The main emphasis of Dr. Maddahi's patient care is prevention of cardiovascular diseases. Dr. Maddahi views patient care as a unique opportunity to apply his more than 30 years of research experience to diagnose patients with cardiovascular diseases at an early stage and to apply rigorous, state-of-the-art treatments to prolong a functional life.

Dr. Maddahi has been selected, by his peers, as one of the Best Doctors in America and has been listed in the Millennium Edition of Whos Who In Medicine and Healthcare as well as Who are The Best 2000 Doctors In North America. Dr. Maddahi has held key leadership positions in various academic societies. In the Society of Nuclear Medicine, he has served as Chairman of the PET Task Force and a member of the Executive Committee of the Cardiovascular Council. He is past president of the Pacific Southwest Chapter of The Society of Nuclear Medicine. In the American Society of Nuclear Cardiology, Dr. Maddahi is a founding member and Chairman of the Southern California Working Group. In the American Heart Association, he has served as Chairman of the Advanced Cardiac Imaging Committee. He is also a member of the Academy of Molecular Imaging and the American College of Cardiology. Dr. Maddahi is a founding member of the Society of Cardiac CT. Dr. Maddahi has served as a member of the Cardiovascular Study Section of the NIH, The State of California Council of Nuclear Medicine, and the UCLA IRB for protection of human research subjects.

Professor Wim Oyen, MD

Radboud University Nijmegen Medical Center, Dept. of Nuclear Medicine, The Netherlands

Proudly sponsored by Siemens

Dr. Wim Oyen, MD, PhD, is professor of Nuclear Medicine (2001) and chair (2008) of the Department of Nuclear Medicine of the Radboud University Medical Center, Nijmegen, The Netherlands. His main areas of research interest are the development of molecular imaging and targeted radionuclide therapy in cancer and of molecular imaging of inflammatory and infectious diseases. He has led a substantial number of clinical trials and translational studies on these subjects and has published over 450 papers. He is currently serving as research director of the Research Institute of Oncology of the Radboud University Medical Center, Congress President for the Annual European Association of Nuclear Medicine (EANM) 2014 and 2015, member of the EANM Executive Committee and member of the Board of the European CanCer Organisation (ECCO). He is actively involved in the European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group. He is associate-editor of The Journal of Nuclear Medicine and member of the editorial board of The European Journal of Nuclear Medicine and Molecular Imaging.

Australian Speakers

Dr. Fares Al-Ejeh

Senior researcher, ARC Future Fellow, Signal Transduction Laboratory, QIMR Berghofer Medical Research Institute

Dr. Al-Ejeh is a senior researcher and an ARC Future Fellow at the Signal Transduction Laboratory headed by Prof. Kum Kum Khanna, QIMR Berghofer Medical Research Institute (Brisbane, Australia). Dr. Al-Ejeh is leading his Targeted Therapeutics team within the NHMRC funded program in breast cancer (led by Prof. Georgia Chenevix-Trench, Prof. Sunil Lakhani and Prof. Kum Kum Khanna). His main research area is the development of targeted therapies, particularly combinatorial anti-cancer therapeutics, based on molecular and cellular characterisations of cancers. He was awarded his PhD from the University of Wollongong (NSW) in 2005; developing alpha-PAI2 for targeted radionuclide cancer therapy (patented by Pi2 Ltd., Sydney). Dr. Al-Ejeh joined the Experimental Therapeutics Laboratory (Prof. Michael P. Brown) at the Hanson Institute/Royal Adelaide Hospital in 2004. He was funded commercially by Oncaidia Ltd. to develop Apomab®, an agent for cancer radioimaging and radiotherapy patented for Dr. Al-Ejeh and Prof. Brown and is still undergoing development towards clinical testing. More recently, Dr. Al-Ejeh has been developing targeted radioimmunotherapy agents in combination with other treatment modalities against aggressive cancers including triple negative breast cancer, pancreatic adenocarcinoma, and glioblastoma.

Dr Zoe Brady

Diagnostic Imaging Medical Physicist, Radiation Safety Officer, Alfred Hospital, Melbourne.

Zoe undertook a PhD at RMIT University investigating the medical radiation exposure of children in Australia from computed tomography (CT) examinations. Dr Brady is undertaking further research at the University of Melbourne on an Australian epidemiological study examining whether ionising radiation from diagnostic scans in childhood increases the subsequent risk of cancer. Dr Brady lectures regularly on medical physics and radiation protection in the health sector.

Dylan Bartholomeusz MBBS, MD, FRACP

Senior Gastroenterologist and Nuclear Medicine Physician, Royal Adelaide Hospital; Senior Lecturer, The University of Adelaide

Dylan Bartholomeusz is a Senior Gastroenterologist and Nuclear Medicine Physician at the Royal Adelaide Hospital and a Senior Lecturer at University of Adelaide. His interests are in the role Nuclear Medicine in the study of gastrointestinal physiology and diagnosis, inflammation imaging, PET Scanning in gastrointestinal malignancy, breath testing and more recently in new agents for lung perfusion scanning, lymphoscintigraphy in oesophageal cancer using radiolabelled and magnetic nannoparticles and body composition in patients with inflammatory bowel disease and chronic liver disease.

Dr Pratyush Giri MBBS, FRCPA, FRACP

SA Pathology

Dr Giri currently looks after Transfusion Services in the Royal Adelaide Hospital. His interests are in both malignant and non-malignant haematology, with a special interest in the management of lymphoproliferative disorders.

Associate Professor Michael Hofman MBBS, FRACP, FAANMS

Centre for Cancer Imaging, Peter MacCallum Cancer Centre

Proudly sponsored by PETNET Solutions

Associate Professor Michael Hofman is a nuclear medicine physician at the Centre for Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a fellowship at Guy's & St Thomas' in London, and was a consultant at Southern Health and MIA. He has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and radionuclide therapy. He has a vision of improving patient outcomes by using molecular imaging to non-invasively characterise disease thereby enabling improved selection of the most appropriate therapy for an individual patient and better assessment of therapeutic response. He has particular interest in novel F-18 and Ga-68 PET radiotracers, and theranostic applications including neuroendocrine tumours. He has an interest in training the next generation of nuclear medicine specialists and currently serves as the RACP representative on the Joint Specialty Advisory Committee in Nuclear Medicine. He has authored over 80 peer-reviewed articles, abstracts or book chapters, and currently serves as an associate editor for the Journal of Medical Imaging and Radiation Oncology and the American Journal of Nuclear Medicine and Molecular Imaging.

Professor Robert Howman-Giles

Clinical Professor, Discipline of Medical Imaging and Discipline of Paediatrics and Child Health, University of Sydney

Professor Robert Howman-Giles is a Clinical Professor in the Discipline of Medical Imaging and Discipline of Paediatrics and Child Health, University of Sydney. He is Head of the Department of Nuclear Medicine at the Children’s Hospital at Westmead and a Director of Alfred Nuclear Medicine and Ultrasound, RPAH Medical Centre, Newtown, NSW. He has published extensively on the use of nuclear medicine and bone mineral density with over 165 publications in peer reviewed journals, 22 book chapters and 1 book. He has presented many lectures and been an invited speaker at national and international conferences. Professor Howman-Giles has major interests in imaging and therapy in paediatric oncology especially PET/CT applications, skeletal, biliary and renal disorders. He has extensive experience in lymphatic mapping in children and in adult sentinel lymph node imaging in melanoma and breast cancer.

Professor Karen Jones Dip App Sci (Nuclear Medicine), PhD

NHMRC Senior CDA Research Fellow, Discipline of Medicine, The University of Adelaide

Prof Jones has been involved in clinical research for the past 22 years. She initially trained as a nuclear medicine technologist and was awarded the prize for the top nuclear medicine student at the University of South Australia in 1991. She subsequently graduated with a PhD at the University of Adelaide in 1998 (the first nuclear medicine technologist in Australia to do so). She currently holds an NHMRC Senior Clinical Career Development Award, for which she received a prestigious NHMRC Achievement Award as the highest ranked candidate in her category in 2010. Prof Jones’ primary research interests capitalise on her background in medical imaging, utilising scintigraphy and ultrasound to evaluate the role of the gastrointestinal tract in (i) postprandial hypotension and (ii) glycaemic control in diabetes mellitus. Prof Jones has been a chief investigator (CI) on numerous previous NHMRC project grants and is currently a CI on three NHMRC project grants and the NHMRC Centre of Research Excellence - Translating Nutritional Science to Good Health. She has 160 publications, a total of 4728 citations and her ‘h’ index is 40. Prof Jones has presented at local, national and international meetings, including an invited plenary lecture at the 7th World Congress of Nuclear Medicine and Biology, Berlin in 1998. In 1999, she was the recipient of the ANSTO Award (currently the only nuclear medicine technologist to have received this award). Prof Jones plays a major role in research training; in particular, individuals with a nuclear medicine background. She has supervised eight honours and nine PhD students, seven of which have a background in medical imaging. She has served on the executive of ANZSNM committees, including the SA Branches of the ANZSNM and ANZSNM Technologists’ Group, and the National Competency Based Standards Committee. Despite a longstanding career in research, coupled with raising her four young children, Prof Jones has maintained her accreditation in nuclear medicine technology and is a Registered Medical Radiation Practitioner.

Dr James Kollias

Dr James Kollias is a senior consultant surgeon in Breast and Endocrine Surgery the Royal Adelaide Hospital, Senior Visiting Surgeon at BreastScreen SA and senior Lecturer in Surgery at the University of Adelaide. He is previous Chairman of the Breast Section of RACS and founding President of BreastSurgANZ. Dr Kollias helped pioneer SNB surgery in breast cancer in Australia in the late 1990’s, was an executive member of the ANZ SNAC Trialists Group and convened 6 workshops on SNB at the Royal Adelaide Hospital in conjunction with RAH Breast surgeons, Dr Barry Chatterton and members of the Department of Nuclear Medicine. He has published and presented a number of papers on SNB in breast cancer and maintains a strong interest in this area.

Professor Vijay Kumar MSc (Med), PhD.

Clinical Professor, Sydney Medical School, University of Sydney & Radiopharmaceutical Scientist.

Professor Vijay Kumar is a Radiopharmaceutical Scientist at the Department of Nuclear Medicine and PET at Westmead Hospital & The Children’s Hospital at Westmead, Sydney. He is a Clinical Professor at Sydney Medical School, University of Sydney. He worked as a Consultant Radiopharmaceutical Science Expert at the IAEA headquarters in Vienna in 2010. He has been associated with IAEA activities since 2005 on several National consultant missions to develop International Radiopharmacopoeial Monographs and Hospital Radiopharmacy guidelines etc. He trained many overseas candidates at Westmead Hospital under IAEA Fellowship and Scientific visits. His major research focus is in developing 68Ga-PET radiopharmaceuticals for molecular imaging of Infection and Neuroendocrine Tumours. He has been closely associated with University of Mainz for research collaboration. He is an editorial board member of the World Journal of Nuclear Medicine and Biology and has been associated with ISORBE activities (International Society of Radiolabelled Blood Elements). He has been actively associated with ANZSNM Scientific Advisory Panel, IRC (International Relations Committee) and in the bid committee for winning the WFNMB-2018. He has published many book chapters, reviews, peer-reviewed publications and Radiopharmacy modules for IAEA. He has been invited to speak at several international meetings.

Dr Michelle Reintals MBBS, FRANZCR

Michelle is a Breast Radiologist with Breast Screen South Australia and is the Breast Imaging Modality Director at Dr Jones & Partners in Adelaide. Specializing in breast imaging including breast MRI and implant MRI, Michelle has a fellowship from Breast Screen SA (2004) and a mini-fellowship in Breast MRI from Brigham Hospital, Boston and observorship at Memorial Sloan Kettering Cancer Centre, NYC in 2010. Since 2012 she has been undertaking a research study into the MRI Evaluation of PIP Breast Implants, which is a co-investigation with A/Prof M. Middleton from UCSD, USA. Michelle holds positions of committee member of the Breast Imaging Reference Group (BIRG), Breast Imaging Group (BIG) and is a Clinical Image Reviewer for the Royal Australasian College of Radiology Mammography Quality Assurance Program (MQAP).

Professor Christopher C. Rowe MD FRACP

Director of the Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia

Professor Rowe leads a neuroscience PET group at Austin Health that has an outstanding international reputation and current funding of over $1.5 million per year from government, philanthropic and commercial sources. Publication rate of over 20 papers per year in the field of neurodegenerative disease and imaging. Annual citations of >1500 in 2012. Notable first author publications include Neurology (2007) – the first report of amyloid imaging in normal ageing and dementias other than AD (>450 citations) and Lancet Neurology (2008) – the first human trial of a beta-amyloid PET tracer suitable for routine clinical use (>280 citations). His group was awarded the “Best Paper 2012 and 2013, de Leon Prize in Neuroimaging” prize from the US Alzheimer’s Association. Career highlight - receipt of the Kuhl-Lassen Award for Outstanding Contribution to Brain Imaging from the US Society of Nuclear Medicine (SNM) in 2011. The focus of Prof. Rowe’s research continues to be imaging of neurodegenerative diseases for better understanding of these conditions, earlier more accurate detection, and to facilitate development of early therapeutic interventions.

Professor Pamela J Sykes

Professor, Preventive Cancer Biology, Flinders Centre for Innovation in Cancer, Flinders University

Prof Sykes obtained her PhD in somatic cell genetics at the University of Adelaide. She then undertook a post-doctoral position at the University of Oklahoma, USA on bacterial gene cloning before returning to Adelaide to the Flinders University where she was involved in developing molecular methods to study minimal residual disease in childhood leukaemia. During this time she joined the Pathology Service at Flinders Medical Centre, becoming the Department Head of Genetics and Molecular Pathology in 2004, and is a Founding Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia. Her current research is focussed on studying the mechanism of the protective role of low dose ionising radiation. Prof Sykes was appointed as Professor, Preventive Cancer Biology in the Flinders Centre for Innovation in Cancer at Flinders University in 2011. She has collaborative low dose radio-biology projects in Australia, Canada, UK and Italy. Current appointments include membership on state and national committees for radiation protection and research and she is an Associate Editor for the journal Radiation Research.

Lowenthal Lecture

Leighton Barnden

Chief Medical Scientist, Department of Nuclear Medicine, The Queen Elizabeth Hospital

Dr Barnden commenced his medical physics career in 1975 after completing his PhD in X-Ray astronomy and Cosmic Ray Physics, and postdoctoral fellowships in Italy and Canada. He participated in the transition from analog to digital cameras, the development of tomographic imaging and the evolution of clinical software. Involvement with two 3-head cameras in brain and cardiac SPECT in a quantitative research environment led to optimization, calibration and modelling work in SPECT. Clinical research projects with brain SPECT saw him adopt iterative reconstruction and the powerful Statistical Parametric Mapping (SPM) package for voxel-based quantitative analysis. From a database of 100 normal brain SPECT studies, he provided new insights into the interaction of normal ageing with the spatial resolution limitations of SPECT. Lately he has translated his SPECT experience to the quantitative analysis of brain MRI databases in clinical research.

Pioneer Lecturer

Max Bellon

Royal Adelaide Hospital

Max Bellon retired in November 2013 after a 43 year career as a Nuclear Medicine Technologist, for almost all of which he held the position of Chief Technologist. His career spanned four Directors and all but a couple of years of the history of the Nuclear Medicine Department at the RAH/IMVS. Max has overseen the transformation of the Department from the early days of largely in-vitro haematology and imaging using rectilinear scanners, through the introduction, amongst other things, of SPECT, PET, Bone Densitometry, CT in association with nuclear imaging, the change from analogue to digital imaging, the fall of film (manual wet chemistry at the beginning) as well as the competing modalities of CT, ultrasound and MRI. He was the man behind the first practical urea breath testing system which was used all around Australia in the 1990s. He was instrumental in helping develop Technologist training courses and has had a hand in training every Technologist to come through those programs. His legacy in the Australian Nuclear Medicine community is immense.

Read with Experts - CARDIAC

Associate Professor Nathan Better

Nathan Better is a cardiologist and nuclear medicine physician. He trained at the Austin and Alfred Hospitals in Melbourne and then at the Joint Program in Nuclear Medicine at Harvard Medical School in Boston, U.S. He is a Cardiologist and Deputy Director of Nuclear Medicine at Royal Melbourne Hospital and a Cardiologist and Nuclear Cardiologist at Cabrini Hospital. His major interests are nuclear cardiology and cardiac CT, where he serves as a nuclear medicine representative on the Australian conjoint committee for CTCA . He is currently on the editorial board of the Journal of Nuclear Cardiology and is a member of the International Advisory Panel of ASNC.

Read with Experts - PET

Dr Sam Berlangieri, FRACP

Dr Sam Berlangieri is currently the Head of the Clinical PET Program at Austin Health having gained his Fellowship in Nuclear Medicine in 1990 and completing further training at Duke Medical Centre in North Carolina under Dr Ed Coleman. In 1992, he returned to an appointment as Consultant Physician to the Centre for PET at Austin Health and has over 20 years of clinical PET and PET/CT experience. His interests include PET in the staging of lung cancer, PET/SPECT in epilepsy, and image fusion of PET/SPECT with structural imaging modalities and PET in therapy monitoring in oncology. He is actively involved in training and teaching as a IAEA invited speaker in Regional Training Courses, and member of the Joint Specialist Advisory Committee and Training Site Accreditation Committee.

Associate Professor Barry Chatterton

Associate Professor Barry Chatterton has almost 40 year’s experience in Nuclear Medicine, and has been the Director of Nuclear Medicine, Bone Densitometry and PET, Royal Adelaide Hospital for the past 32 Years, and is currently Head of Nuclear Medicine for the (Statewide) SA Medical Imaging. His interests are particularly diagnostic nuclear medicine in oncology and radiopharmaceuticals, and has been active in diagnostic ultrasound since its inception in SA.

Conference Highlights

Ghee Chew MBBS FRACP FAANMS

Renal and Nuclear Physician

Dr Chew has been a Nuclear Medicine Physician since 2000. In Ghee’s current appointment at the Royal Adelaide Hospital in private practice he actively performs all modalities of scintigraphic imaging including holding certification in PET. Ghee has special interests in nuclear cardiology, renal and musculoskeletal scintigraphy. Ghee is also a Renal Physician with the Renal Unit at the Royal Adelaide Hospital. He holds level A CT coronary angiography accreditation.

Sponsors

Platinum - InSight